Medical Equipment

Cardiac Marker Testing Market Developments Driving Growth Across The Forecast Period

April 10, 2026April 10, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Cardiac Marker Testing Market Expected To Reach Based On Its 2026 Value?

The cardiac marker testing market size has demonstrated rapid expansion in recent years. It is anticipated to increase from $7.19 billion in 2025 to $7.93 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic period is attributable to the limited availability of high-sensitivity cardiac marker tests, a reliance on centralized laboratory testing, the growing prevalence of cardiovascular diseases, increasing awareness among healthcare providers, and conventional manual diagnostic practices.

The cardiac marker testing market is projected to experience swift expansion in the upcoming years. Its valuation is set to reach $11.61 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth throughout the forecast period can be primarily linked to the creation of automated and portable cardiac marker testing tools, the increasing acceptance of point-of-care diagnostic methods, their incorporation into digital health systems, the expanding elderly demographic and associated cardiovascular risks, and enhancements in the sensitivity of reagents and testing kits. Key trends identified for the forecast timeframe encompass the increasing utilization of high-sensitivity cardiac biomarker tests, the broadening availability of point-of-care testing locations, the merging of automated analyzers with immunoassay systems, the expanding application of cardiac marker testing within preventive cardiology, and a rising need for portable diagnostic equipment.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19358&type=smp

Which Important Drivers Are Guiding The Cardiac Marker Testing Market Growth?

An increasing occurrence of cardiovascular diseases is anticipated to boost the expansion of the cardiac marker testing market in the future. Cardiovascular diseases (CVDs) encompass various conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The growing number of cardiovascular disease cases stems from factors like an unhealthy diet, lack of physical activity, tobacco consumption, excessive alcohol use, and air pollution. Cardiac marker testing is essential for cardiovascular diseases to precisely diagnose, evaluate severity, and track the progression or treatment response of heart ailments through the detection of specific biomarkers released during heart muscle damage. For instance, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000, which is an increase of 4.0% from 224.4 per 100,000 compared to 2023. Consequently, the rising frequency of cardiovascular diseases propels the cardiac marker testing market.

Which Segment Types Are Examined In The Cardiac Marker Testing Market Segment Study?

The cardiac marker testing market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments

2) By Biomarker Type: Troponin I And T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Other Biomarker Types

3) By Application: Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions

Subsegments:

1) By Reagents and Kits: Troponin Test Kits, B-type Natriuretic Peptide (BNP) Test Kits, Creatine Kinase-MB (CK-MB) Test Kits, Myoglobin Test Kits, Other Cardiac Biomarker Reagents

2) By Instruments: Point-Of-Care Testing Devices, Automated Analyzers, Immunoassay Systems, Portable Diagnostic Devices

What Trends Are Influencing The Evolution Of The Cardiac Marker Testing Market?

Leading companies in the cardiac marker testing market are dedicated to developing technologically advanced products, such as cardiac assays, to provide valuable and precise insights into heart health and function. Cardiac assays are diagnostic tools designed to measure biomarkers or other indicators in blood or other samples to evaluate heart function, diagnose cardiovascular conditions, or assess the risk of heart-related issues. For instance, in October 2023, Mindray, a China-based medical device company, launched its troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTnI assay distinguishes itself with exceptional sensitivity, precision, and reliability, surpassing minimum requirements by achieving a 93% detection rate between the limit of detection (LoD) and the 99th percentile upper reference limit (URL) and maintaining an imprecision coefficient of variation (CV) below 5% at the 99th URL, making it highly effective in detecting myocardial injury. Mindray’s NT-proBNP assay is an important cardiac marker for heart failure, demonstrating high precision with a coefficient of variation (CV) of ≤5%. It also effectively minimizes interference from 55 common heart disease medications, ensuring accurate detection and management of heart failure.

Which Players Are Part Of The Competitive Landscape Of The Cardiac Marker Testing Market?

Major companies operating in the cardiac marker testing market are F. Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, Guangzhou Wondfo Biotech Co. Ltd., Randox Laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Alere Inc., Nano‑Ditech Corporation, Ortho Clinical Diagnostics, QuidelOrtho Corporation, DiaSorin S.p.A., PerkinElmer Inc., Meso Scale Diagnostics LLC, Boditech Med Inc., Response Biomedical Corp.

Get The Full Cardiac Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiac-marker-testing-global-market-report

Where Is The Cardiac Marker Testing Market Primarily Concentrated By Region?

North America was the largest region in the cardiac marker testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cardiac Marker Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=19358&type=smp

Browse Through More Reports Similar to the Global Cardiac Marker Testing Market 2026, By The Business Research Company

Ventricular Assist Device Market Report 2026

https://www.thebusinessresearchcompany.com/report/ventricular-assist-device-global-market-report

Left Ventricular Assist Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/left-ventricular-assist-devices-global-market-report

Interventional Cardiology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795